论文部分内容阅读
自８０年代初开始在全国７个有代表性的省市进行了Ａ群脑膜炎菌苗不同免疫方案的研究。根据菌苗对不同年龄组人群的免疫反应性及持久性制订的免疫方案，经过８～１０年的观察，各省市均有效的控制了８０年代的流脑流行，使发病率下降至有史以来最低水平。经监测证明，８０年代流行的Ａ群脑膜炎菌与６０年代相同，均为ＣｌｏｎｅⅢ－Ｉ型，它曾引起世界性流行。接种菌苗的最适免疫剂量证实为３０μｇ，比国际通用剂量少２０μｇ。对不同免疫方案的评价指出：方案的制订主要依靠本地区的监测及预测工作，综合预测分析法和Ｂａｙｅｓ概率法早期预测具有较高的实用价值。人群抗体水平及Ａ群带菌率是流脑动力学及预测流行的重要指标。最佳免疫方案是在预测流行到来之前对易感人群进行一次性普种，要求复盖率达８５％～９０％以上。其后对６月～２岁的婴幼儿每年基础免疫１针，共２针，间隔１年，有利于降低低年龄组的发病专率，且能提高人群的免疫反应性，起到延长流行间歇期的作用。这种免疫方案经济效益最高。
Since the early 1980s, a group of meningitis vaccine different immunization programs have been studied in seven representative provinces and cities nationwide. According to the immunological reactivity of vaccine against different age groups and the durable immunization program, all provinces and municipalities effectively controlled the meningococcal epidemic in the 1980s after 8 to 10 years of observation, reducing the incidence to the lowest ever Level. Proved by surveillance, the meningitis group A in the 1980s was the same as the type I in the 1960s and was Clone III-I, which has caused worldwide epidemics. The optimal immunization dose of vaccinated vaccine was confirmed to be 30μg, 20μg less than the internationally accepted dose. The evaluation of different immunization programs indicates that the formulation of the program mainly depends on the monitoring and forecasting work in the region, and the comprehensive predictive analytic method and the Bayes probability method are of high practical value. Population antibody levels and group A colonization rates are important indicators of meningococcal kinetics and prediction of prevalence. The best immunization program is to make a one-time universal epidemic of susceptible people before the epidemic is predicted, requiring a coverage rate of 85% -90%. Subsequent 6-year-old to 2-year-old infant basic immunization every year, a total of 2 needles, an interval of 1 year, is conducive to reducing the incidence of low-age group rate, and can improve the population’s immune reactivity, to extend the epidemic of intermittent The role of period. This immunization program has the highest economic benefits.